Clinical trial NCT01555099: Multi-centre Study to Assess the Efficacy and Safety of AZD5423 in COPD Patients on a Background Therapy of Formoterol
Official title: A Phase-II, Double-blind, Placebo-controlled, Randomised, Parallel-group,Multi-centre Study to Assess the Efficacy and Safety of Two Staggered Dose Levels of Inhaled Once Daily AZD5423 or Twice Daily Budesonide for 12 Weeks in COPD Patients on a Background Therapy of Formoterol.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Keywords: COPD, FEV1, AZD5423
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2012-03-15
Enrollment: 353
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to assess the efficacy and safety of two staggered dose levels of inhaled once daily AZD5423 or twice daily budesonide for 12 weeks in COPD patients on a background therapy of formoterol.

Detailed description: A phase-II, double-blind, placebo-controlled, randomised, parallel-group,multi-centre study to assess the efficacy and safety of two staggered dose levels of inhaled once daily AZD5423 or twice daily budesonide for 12 weeks in COPD patients on a background therapy of formoterol.

Eligibility criteria: Inclusion Criteria:

* Provision of signed and dated informed consent prior to conducting any study specific procedures
* Men or women aged ≥ 40 years
* Men or post-menopausal or surgically sterile women. Women will be considered post-menopausal if they have been amenorrheic for at least 12 months, and have a follicle stimulating hormone (FSH) plasma concentration within the postmenopausal range as defined by the laboratory. Male patients should be willing to use barrier contraception, i.e. condom (with spermicide) from the day of dosing until at least 5 weeks after the last dose with the study drug.
* Clinical diagnosis of COPD for more than 1 year at Visit 1, according to GOLD guidelines
* Current maintenance therapy with LABA and/or LAMA, ICS/LABA or ICS plus LAMA combination
* Current or ex-smokers with a smoking history equivalent to at least 10 pack years (1 pack year = 20 cigarettes smoked per day for one year)
* Post-bronchodilator FEV1 ≥40 and ≤ 80% of the predicted normal value
* Post-bronchodilator FEV1/FVC \<0,7
* Reversibility of airway obstruction according to reversibility test performed at visit 2, defined as an increase in FEV1 of ≥10% relative baseline after inhalation of in total 400 μg salbutamol or 1 mg terbutaline sulphate
* Chest radiography (not older than 12 months at Visit 2) not showing any pathological changes that would make the patient unsuitable for inclusion as judged by the Investigator
* Able to read and write and use the electronic devices (eDiary and electronic spirometry)
* Ability to complete an eDiary correctly. Baseline diary data had to be recorded for at least 8 (any 8) of the last 10 days of the run-in period to accept patients for randomized treatment (Randomisation Criteria at Visit 3).
* Provision of informed consent for genetic sampling and analyses. If a patient declines to participate in the pharmacogenetic research, there will be no consequence or loss of benefit to the patient. The patient will not be excluded from other aspects of the study described in the Clinical Study Protocol (CSP), as long as they consent (Inclusion criteria for patients taking part in the pharmacogenetic research)

Exclusion Criteria:

* Significant disease or disorder (eg, cardiovascular, pulmonary other than COPD, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or influence the results of the study, or the patient's ability to participate in the study
* Any clinically relevant abnormal findings in clinical chemistry, haematology, urinalysis, physical examination, pulse, blood pressure or ECG at Visit 2, which, in the opinion of the investigator, may put the patient at risk because of his/her participation in the study
* Requirement for long term oxygen therapy
* An exacerbation of COPD, defined as use of oral or parenteral glucocorticosteroids or oral/parenteral antibiotics or hospitalisation related to COPD within 6 weeks of Visit 2
* Participation in or scheduled for an intensive COPD rehabilitation program
* Known or suspected hypersensitivity to study therapy or excipients of the study drug
* History of current alcohol or drug abuse or any condition associated with poor compliance as judged by the investigator
* Plasma donation within one month of screening or any blood donation/blood loss \>500 mL during the 3 months prior to screening.
* Participation in any clinical study with an investigational drug or new formulation of a marketed drug in the 3 months prior to Visit 2
* Planned in-patient surgery or hospitalisation during the study
* Previous randomisation of treatment into the present study
* Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)
* Previous allogeneic bone marrow transplant (Exclusion criteria for patients taking part in the pharmacogenetic research)
* Non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection (Exclusion criteria for patients taking part in the pharmacogenetic research)

Primary outcomes:
measure: Absolute change from baseline to mean of weeks 8 to 12 in pre-dose forced expiratory volume in 1 sec (FEV1)
timeFrame: Baseline (week 0), and at week 8, 10, and 12
Secondary outcomes:
measure: Percent change from baseline in twenty-four hour plasma cortisol
timeFrame: Baseline (week 0), and at week 4 and 12
measure: Time to first exacerbation (hospitalisation, oral/parenteral corticosteroid, oral/parenteral antibiotics)
timeFrame: Baseline(week 0) and week 2, 4, 8, 10, 12 and daily by eDairy
measure: The percent change from baseline in pre-dose hsCRP at week 4 and 12
timeFrame: Baseline(week 0), and at week 4 and 12
measure: Profile of pharmacokinetics (PK) of AZD5423 in terms of Cmax, tmax, AUC(0-24h), CL/F, Cav in subset of patients
timeFrame: Week 4 and 12
measure: Number of St George's Respiratory Questionnaire (SGRQ-C) responders and Overall Score
timeFrame: Baseline(week 0), and at week 4 and 12
measure: Assessment of Baseline/Transitional Dyspnea Index (BDI/TDI) Score
timeFrame: Baseline(week 0), and at week 4 and 12
measure: Assessment of Breathlessness, Cough and Sputum Scale (BCSS) Score
timeFrame: Daily by eDairy
measure: Absolute change from baseline to mean of week 2 and 4 pre-dose forced expiratory volume in 1 sec (FEV1)
timeFrame: Baseline (week 0), and at week 2 and 4.
measure: Absolute change from baseline in pre-dose FEV1
timeFrame: Baseline (week 0) and at week 2, 4, 8, 10 and 12
Other outcomes:
Locations:
city: Doganovo
country: Bulgaria
facility: Research Site
city: Plovdiv
country: Bulgaria
facility: Research Site
city: Sofia
country: Bulgaria
facility: Research Site
city: Varna
country: Bulgaria
facility: Research Site
city: Brest Cedex 2
country: France
facility: Research Site
city: Marseille Cedex 20
country: France
facility: Research Site
city: Montpellier
country: France
facility: Research Site
city: Nice Cedex 01
country: France
facility: Research Site
city: Pessac
country: France
facility: Research Site
city: Balassagyarmat
country: Hungary
facility: Research Site
city: Budapest
country: Hungary
facility: Research Site
city: Deszk
country: Hungary
facility: Research Site
city: Szazhalombatta
country: Hungary
facility: Research Site
city: Foggia
country: Italy
facility: Research Site
state: FG
city: Padova
country: Italy
facility: Research Site
state: PD
city: Verona
country: Italy
facility: Research Site
state: VR
city: Napoli
country: Italy
facility: Research Site
city: Pisa
country: Italy
facility: Research Site
city: Bialystok
country: Poland
facility: Research Site
city: Gorzow Wlkp
country: Poland
facility: Research Site
city: Lodz
country: Poland
facility: Research Site
city: Proszowice
country: Poland
facility: Research Site
city: Tarnow
country: Poland
facility: Research Site
city: Barnaul
country: Russian Federation
facility: Research Site
state: Russia
city: Chelyabinsk
country: Russian Federation
facility: Research Site
city: Ekaterinburg
country: Russian Federation
facility: Research Site
city: Moscow
country: Russian Federation
facility: Research Site
city: Novosibirsk
country: Russian Federation
facility: Research Site
city: Saint Petersburg
country: Russian Federation
facility: Research Site
city: Vladikavkaz
country: Russian Federation
facility: Research Site
city: Yaroslavl
country: Russian Federation
facility: Research Site
city: Bratislava
country: Slovakia
facility: Research Site
city: Humenne
country: Slovakia
facility: Research Site
city: Kosice
country: Slovakia
facility: Research Site
city: Spisska Nova Ves
country: Slovakia
facility: Research Site
city: Vrable
country: Slovakia
facility: Research Site
city: Zvolen
country: Slovakia
facility: Research Site
city: Donetsk
country: Ukraine
facility: Research Site
city: Ivano-frankivsk
country: Ukraine
facility: Research Site
city: Kharkiv
country: Ukraine
facility: Research Site
city: Kyiv
country: Ukraine
facility: Research Site
city: Odesa
country: Ukraine
facility: Research Site
city: Poltava
country: Ukraine
facility: Research Site
city: Zaporizhzhya
country: Ukraine
facility: Research Site
Study officials:
affiliation: Uniwersytecki Szpital Kliniczny nr 1 im. N. Barlickiego w Łodzi, ul. Kopcińskiego 22, 90-153, Łódź, Poland
name: Piotr Kuna, Professor
role: PRINCIPAL_INVESTIGATOR
References: